1-5 of 5
Harpreet S. Bajaj
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Continuous Glucose Monitoring–Based Metrics and Hypoglycemia Duration in Insulin-Experienced Individuals With Long-standing Type 2 Diabetes Switched From a Daily Basal Insulin to Once-Weekly Insulin Icodec: Post Hoc Analysis of ONWARDS 2 and ONWARDS 4

Free
Harpreet S. Bajaj, Björg Ásbjörnsdóttir, Lisbeth Carstensen, Christian Laugesen, Chantal Mathieu, Athena Philis-Tsimikas, Tadej Battelino
Journal: Diabetes Care
Diabetes Care 2024;47(4):729–738
https://doi.org/10.2337/dc23-2136
Published: 21 February 2024
View articletitled, Continuous Glucose Monitoring–Based Metrics and Hypoglycemia Duration in Insulin-Experienced Individuals With Long-standing Type 2 Diabetes Switched From a Daily Basal Insulin to Once-Weekly Insulin Icodec: Post Hoc Analysis of ONWARDS 2 and ONWARDS 4
Open the PDF for Continuous Glucose Monitoring–Based Metrics and Hypoglycemia Duration in Insulin-Experienced Individuals With Long-standing Type 2 Diabetes Switched From a Daily Basal Insulin to Once-Weekly Insulin Icodec: Post Hoc Analysis of ONWARDS 2 and ONWARDS 4 in another window
Journal Articles

Impact of Canagliflozin on Kidney and Cardiovascular Outcomes by Type 2 Diabetes Duration: A Pooled Analysis of the CANVAS Program and CREDENCE Trials

Free
Sheldon W. Tobe, Thomas A. Mavrakanas, Harpreet S. Bajaj, Adeera Levin, Navdeep Tangri, April Slee, Brendon L. Neuen, Vlado Perkovic, Kenneth W. Mahaffey, Wally Rapattoni, Fernando G. Ang
Journal: Diabetes Care
Diabetes Care 2024;47(3):501–507
https://doi.org/10.2337/dc23-1450
Published: 22 January 2024
View articletitled, Impact of Canagliflozin on Kidney and Cardiovascular Outcomes by Type 2 Diabetes Duration: A Pooled Analysis of the CANVAS Program and CREDENCE Trials
Open the PDF for Impact of Canagliflozin on Kidney and Cardiovascular Outcomes by Type 2 Diabetes Duration: A Pooled Analysis of the CANVAS Program and CREDENCE Trials in another window
Journal Articles

Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial

Free
Frederik Persson, Peter Rossing, Priya Vart, Glenn M. Chertow, Fan Fan Hou, Niels Jongs, John J.V. McMurray, Ricardo Correa-Rotter, Harpreet S. Bajaj, Bergur V. Stefansson, Robert D. Toto, Anna Maria Langkilde, David C. Wheeler, Hiddo J.L. Heerspink
Journal: Diabetes Care
Diabetes Care 2021;44(8):1894–1897
https://doi.org/10.2337/dc21-0300
Published: 28 June 2021
View articletitled, Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial
Open the PDF for Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial in another window
Journal Articles

Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial

Free
Harpreet S. Bajaj, Richard M. Bergenstal, Andreas Christoffersen, Melanie J. Davies, Amoolya Gowda, Joakim Isendahl, Ildiko Lingvay, Peter A. Senior, Robert J. Silver, Roberto Trevisan, Julio Rosenstock
Journal: Diabetes Care
Diabetes Care 2021;44(7):1586–1594
https://doi.org/10.2337/dc20-2877
Published: 19 March 2021
View articletitled, Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial
Open the PDF for Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial in another window
Journal Articles

Lowest Glucose Variability and Hypoglycemia Are Observed With the Combination of a GLP-1 Receptor Agonist and Basal Insulin (VARIATION Study)

Free
Harpreet S. Bajaj, Karri Venn, Chenglin Ye, Avril Patrick, Shivani Kalra, Hasnain Khandwala, Nadeem Aslam, David Twum-Barima, Ronnie Aronson
Journal: Diabetes Care
Diabetes Care 2017;40(2):194–200
https://doi.org/10.2337/dc16-1582
Published: 02 December 2016
View articletitled, Lowest Glucose Variability and Hypoglycemia Are Observed With the Combination of a GLP-1 Receptor Agonist and Basal Insulin (VARIATION Study)
Open the PDF for Lowest Glucose Variability and Hypoglycemia Are Observed With the Combination of a GLP-1 Receptor Agonist and Basal Insulin (VARIATION Study) in another window